Search Thermo Fisher Scientific
Diploid Growth and Production Media for Vaccine Production
Helps reduce risk, cost and the danger of adventitious agents
Now you can transition to a reduced-serum medium for human diploid cells without sacrificing cell growth or virus expression. Gibco diploid serum-reduced medium (SRM) is a combination of two media to support vaccine manufacture under serum-reduced or serum-free conditions with human diploid cells such as MRC-5, Wl-38, KMB17, 2BS, as well as chicken embryo fibroblasts (CEF).
When culturing human diploid cells such as MRC-5, WI38, and KMB17 cell growth may be accomplished with 1–2% serum. Additionally, CEFs may be cultured serum-free. Virus production can then be conducted under serum-free conditions without the addition of serum or albumin.
Diploid Growth Medium Kit—for cell growth and scale-up for vaccine production
The Diploid Growth SRM Kit is designed to support growth of human diploid cells with only 1% to 2% serum. When paired with the Diploid Production SFM, the kit provides comparable growth and virus titers to conventional medium supplemented with 5–10% serum.
Diploid Production Medium Kit—for virus expression post infection of cell culture
The Diploid Production SFM is designed to support virus production with human diploid cells without adding serum. When used with the Diploid Growth SRM, the kit provides comparable growth and virus titers to conventional medium supplemented with serum or albumin.
Diploid SRM offers many benefits that a serum-containing complete medium does not, including
- Titer comparable to a serum-containing process
- Reduce process exposure to serum
- Lower cost due to reduction or elimination of serum
- Reduced risk of interrupted supply
- A better-defined source of nutrition to the cells
- Available in dry format (DPM) with liquid supplement*
Significantly higher productivity leads to higher virus production
Human cells have been used to manufacture a variety of vaccines such as varicella-zoster, polio, smallpox, hepatitis A, measles, mumps and rubella. Traditionally, the only way to culture these cells has been to utilize classical media with 10% serum, one of the highest-cost components in the vaccine process. Human and recombinant human albumin, which is traditionally used in virus production media, also tends to be expensive. Diploid SRM helps with the reduction or elimination of both while maintaining high virus titers for vaccine production.
Growth of CEFs in Diploid Growth SRM
Figure 1. Chicken Embryo Fibroblast growth with classical medium supplemented with 10% FBS and Diploid Growth SRM without serum supplementation. Cells were seeded from a fresh egg prep at 1.5 x 105 cells/cm2
Growth of MRC-5 cells in Diploid Growth SRM
Figure 2. MRC-5 cells were seeded at 1.5 x 104 cells/cm2, incubated for 4 days and trypsinized.
Varicella Zoster Virus Production
Figure 3. MRC-5 cells were seeded at 1.5x104 cells/cm2, incubated for 4 days, infected with Varicella Zoster Virus (VZV) at MOI 0.01 and harvested 3 days post infection. Titers were determined with TCID50.
Related resources
Application note: Diploid Serum-Reduced Medium system supports viralproduction and outperforms in specific productivity
Application note:Diploid Growth Serum-Reduced Medium can reduce or eliminate serum use in human and animal vaccine production
Brochure:Streamline viral vector and vaccine development
Brochure:Vaccine Production Cell Culture
Bioprocessing resources
Access a targeted collection of scientific application notes, case studies, posters, white papers and more for bioprocessing:
Support
Events & Webinars
For Research Use Only. Not for use in diagnostic procedures.